Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. End stage renal disease (ESRD) patients on hemodialysis for at least 3 months.~2. Serum C reactive protein level of ≥ 0.8 mg/dl.~3. Serum albumin \< 3.8 g/dl (BCG).~4. Signing a written informed consent form.~5. Willingness and ability to comply with the FDA-mandated S.T.E.P.S ® program.~6. Age \> 18 years.~Exclusion Criteria:~1. Pregnant and/ or lactating female.~2. Active infection within the previous 8 weeks requiring administration of antibiotics.~3. Patients receiving systemic immunosuppressive therapy.~4. Patients with HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: ACTIVE_COMPARATOR): 1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide.
- No Drug (Type: PLACEBO_COMPARATOR): 1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive Placebo (Sugar pill) for a period of 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).